Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Allergan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Allergan

BOTOX drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan

4Q Revenues: $3.9 billion (+7%)

4Q Earnings: $1.2 billion (loss of $629.3 million 4Q15)

FY Revenues: $14.6 billion (+15%)

FY Earnings: $15.0 billion (earnings were $3.9 billion FY15)

Comments: Growth in the quarter was driven by BOTOX Cosmetic, with $199.4 million in sales, up 18% reflecting continued volume growth, and BOTOX Therapeutic revenues of $313.5 million, up 14%. KYBELLA, which launched in August, had sales of $12 million in the quarter. LINZESS sales were $173.6 million in the quarter, up 34% driven primarily by strong demand and continued OTC conversion. RESTASIS revenues were $393.1 million in the quarter, up 13% driven by demand and pricing. Earnings include discontinued operations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters